Open Orphan PLC Article published in Drug Discovery Today
January 21 2021 - 2:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
21 January 2021
Open Orphan plc
("Open Orphan" or the "Company")
Article Published in Drug Discovery Today
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
pharmaceutical services clinical research organization (CRO) and a
world leader in vaccine and antiviral testing using human challenge
clinical trials, announces an article submission has been published
in Drug Discovery Today, a print and online trade magazine with an
emphasis on the science which underpins drug discovery and
development. The published editorial is titled "Modelling the World
- can deliberately infecting healthy volunteers really tell us much
about what happens outside the clinic during an epidemic or
pandemic?"
The article was written by Adrian Wildfire, Director of
Scientific and Business Strategy at hVIVO , part of Open Orphan
plc. Adrian is a specialist in the fields of virology, medical
microbiology and parasitology.
The article explores what can be learned from using the method
of human challenge trials to support vaccine development, and
focuses on the role hVIVO plays in this, in particular in relation
to COVID-19. hVIVO has a long history of successfully delivering
human challenge studies at their state-of-the-art quarantine
facility in East London.
To view the article, please follow the link:
https://bit.ly/3nLct9Q
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . hVIVO welcomes volunteers under expertly
supervised conditions, to further medical research, and help us to
take the understanding of respiratory illnesses to a new level.
Volunteers are central to the work that we do; our studies focus on
testing new treatments on real people, in a safe, controlled,
clinical environment.
Further details on all aspects of our volunteer programs
including testimonials from previous volunteers can be found at
www.flucamp.com .
If you are interested in being contacted and provided with
details about future COVID-19 human challenge study research,
please leave your contact details at www.UKCovidChallenge.com .
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & +44 (0)20 7933 8780 or openorphan@walbrookpr.com
IR)
+44 (0)7876 741 001 / +44
Anna Dunphy / Paul McManus (0)7980 541 893
About Open Orphan ( www.openorphan.com )
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is a world leader in the testing of vaccines
and antivirals through the use of human challenge clinical trials.
Conducted from Europe's only 24-bedroom quarantine clinic with
onsite virology providing individually isolated rooms and connected
to our specialist laboratory facility. hVIVO's challenge studies
require healthy volunteers to take part, volunteers are recruited
through FluCamp, learn more at www.FluCamp.com . The hVIVO facility
offers highly specialised virology and immunology laboratory
services to support pre-clinical and clinical respiratory drug,
antiviral, and vaccine discovery and development. Reliable
laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also building out a
valuable data platform business. hVIVO has built up one of the
world's largest databases of infectious disease progression data
and we are populating our Open Orphan Health Data platform with
this historical hVIVO data. In our clinical trials going forward,
we are also planning to collect data on volunteers via wearables
during clinical trials. Therefore, Open Orphan's data, which may
yield valuable digital biomarkers, could be one of the more
sought-after datasets by many of the large wearables /smart watch
wearables providers around the world. In June 2019, Open Orphan
acquired AIM-listed Venn Life Sciences Holdings plc in a reverse
take-over and in January 2020 it completed the merger with hVIVO
plc. Venn is an integrated drug development consultancy firm which
offers CMC (chemistry, manufacturing and controls), preclinical,
Phase I & II clinical trials design and execution. The merger
with hVIVO created a European full pharma services company
broadening the Company's customer base and with complementary
specialist CRO services, widened the range of the Company's service
offerings.
About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute non-regulatory news releases into
the public domain. Information required to be notified under the
AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABRGDBUUDDGBG
(END) Dow Jones Newswires
January 21, 2021 02:00 ET (07:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024